Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.9M | $43.0M | $94.4M | $118M | $0.00 | $0.00 | $14.2M | $26.8M | $36.5M | $54.0M |
| Revenue growth | — | -38.5% | 119.4% | 24.9% | -100.0% | — | — | 88.4% | 36.1% | 48.0% |
| Operating income | -$201M | -$321M | -$362M | -$316M | -$336M | -$378M | -$389M | -$391M | -$426M | -$472M |
| Operating margin | -287.6% | -745.8% | -384.0% | -268.2% | — | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Net income | -$198M | -$315M | -$346M | -$411M | -$327M | $1.60B | -$232M | -$352M | $674M | -$413M |
| Net margin | -284.0% | -731.6% | -366.6% | -349.0% | — | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (diluted) | -$5.07 | -$6.75 | -$6.03 | -$6.86 | -$4.74 | $26.55 | -$4.23 | -$6.33 | $11.64 | -$7.12 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $38.6M | -$285M | -$304M | -$371M | -$291M | -$407M | -$309M | -$296M | -$390M | -$373M |
| Capital expenditures | $9.91M | $4.63M | $6.99M | $12.0M | $14.1M | $5.74M | $4.88M | $999K | $1.69M | $4.32M |
| Free cash flow | $28.6M | -$290M | -$311M | -$383M | -$305M | -$413M | -$314M | -$297M | -$392M | -$377M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $161M | $103M | $70.5M | $80.9M | $127M | $203M | $139M | $88.2M | $76.2M | $89.1M |
| Total assets | $619M | $614M | $858M | $891M | $853M | $1.44B | $1.24B | $937M | $1.66B | $1.30B |
| Total liabilities | $261M | $239M | $171M | $250M | $453M | $146M | $138M | $126M | $122M | $104M |
| Shareholders' equity | $359M | $376M | $688M | $641M | $400M | $1.29B | $1.10B | $811M | $1.54B | $1.19B |
| Retained earnings | -$483M | -$798M | -$759M | -$1.52B | -$1.84B | -$239M | -$471M | -$823M | -$149M | -$562M |
| Shares (wtd avg diluted) | 42.2M | 48.8M | 58.2M | 60.0M | 69.0M | 60.4M | 54.8M | 55.7M | 57.9M | 58.0M |
Every figure is extracted from AGIOS PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.